Fast Market Research recommends "Qatar Pharmaceuticals & Healthcare Report Q4 2014" from Business Monitor International, now available

Boston, MA -- (SBWire) -- 10/23/2014 --The reduction of a large number of medicine prices in Qatar is likely to be detrimental to pharmaceutical companies' revenue potential. New drug pricing - which was previously very high in the country - will increase the volume of sales, as medicines will become more affordable, partially counteracting losses from price reduction. Economic and political stability, in addition to projected growth in the pharmaceutical and healthcare markets, will ensure that Qatar remains a small but attractive market.

Headline Expenditure Projections

- Pharmaceuticals: QAR1.63bn (USD449mn) in 2013 to QAR1.84bn (USD504mn) in 2014; +12.4% in local currency and 12.4% in US dollar terms. Forecast slightly higher than in Q314.

- Healthcare: QAR17.06bn (USD4.69bn) in 2013 to QAR18.84bn (USD5.17bn) in 2014; +10.4% in both local currency and US dollar terms. Forecast revised upwards due to macroeconomic modifications.

View Full Report Details and Table of Contents

Risk/Reward Rating: Qatar's risks are particularly low in comparison with the rest of the MEA region, although its potential rewards are dampened by the small market size. Nevertheless, Qatar's high level of urbanisation, rapid population growth and rising prevalence of chronic lifestyle diseases creates an environment in which there is strong potential for market growth. On account of shifts within BMI's Pharmaceutical Risk/Reward Rating Index for the Middle East and Africa matrix in Q414, Qatar has moved again down two positions in the MEA matrix to seventh place with the country's scores this quarter remaining 53.5 out of 100.

Key Trends And Developments

In August 2014, the Qatar National Research Fund (QNRF) will spend 24% of its funding on healthcare and medical research, focussing on diabetes, cancer and heart disease, reports Qatar Health magazine, citing Director Abdul Sattar Al Taie. 'This will help Qatar build research capacity by interacting with researchers around the world and build research culture,' said Al Taie, reports...

The Qatar Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Qatar Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Qatari pharmaceutical and healthcare industry.

Key Benefits

- Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Qatar to test other views - a key input for successful budgeting and strategic business planning in the Qatari pharmaceutical and healthcare market.

- Target business opportunities and risks in the Qatari pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Qatar.

- Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 800-844-8156

Browse all Healthcare research reports at Fast Market Research